Regeneron Pharmaceuticals, Inc. (REGN) income statement
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Regeneron Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 28.8%
- Net margin
- 28.5%
- Return on equity, FY2025
- 14.9%
Financial strength
- Current ratio
- 3.35
- Debt to equity
- 0.06
- Debt to assets
- 4.5%
- Cash to current liabilities
- 59.0%
Valuation
- P/E ratio
- 20.9
- Price to sales
- 5.79
- Price to book
- 2.92
- Dividend yield
- –
See a number that looks wrong?